Novartis

Novartis Foundation to Focus Fully on How Digital, Data and AI Can Transform Global Health

The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health.
Press Release

BASEL, Switzerland, July 8, 2019 /3BL Media/ – The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health. This new mandate builds on 40 years of striving for sustainable impact on health in low-income populations, most recently by focusing on leprosy elimination and cardiovascular health, in addition to digital health.

Uncovering Sickle Cell Disease

Article

Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3

New Public-Private Partnership to Strengthen Primary Healthcare in Vietnam

The Working Group for Primary Healthcare Transformation should complement the government’s efforts to strengthen primary healthcare to achieve Universal Health Coverage (UHC) in Vietnam.
Press Release

HANOI, Vietnam, May 21, 2019 /3BL Media/– A new public-private partnership, comprising the Vietnamese Ministry of Health, and three other founding members, i.e. World Economic Forum (WEF), Harvard Medical School Center for Primary Care and Novartis could transform primary healthcare in Vietnam. As announced by the Vietnamese Ministry of Health, this innovative public-private partnership will help deliver on the Ministry of Health’s objectives the Vietnamese Ministry of Health by strengthening existing primary care demonstration projects in 30 provinces.

Asian Malaria Endgame Threatened by Resistance to Insecticides and Malaria Treatments

Asian experts surveyed in a new report fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease.
Summary: 
  • Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
  • Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
  • Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services
Press Release
  • Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
  • Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
  • Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services

Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug

Summary: 
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
Press Release
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.

Novartis Foundation and Microsoft Partner to Develop AI-Enabled Digital Health Tool for Early Leprosy Detection

The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy
Press Release

BASEL, Switzerland, March 26, 2018 /3BL Media/  – The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy. Over 200,000 people are diagnosed with leprosy every year. Brazil, India, and Indonesia account for about 80% of new cases. If untreated, patients are left with lifelong disabilities and are often stigmatized in their societies.

Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy

Summary: 
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5

Novartis Receives FDA Approval for Egaten® for the Treatment of Fascioliasis, a Neglected Tropical Disease

Summary: 
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Press Release
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Novartis Releases Novartis in Society 2018 Report

Article

For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).

Sandoz Certified Global Top Employer 2019

Summary: 
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy
Press Release
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy

Pages

Subscribe to Novartis